Mirae Asset Healthcare Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?
- September 15, 2026
- Posted by: Chaitanya Auti
- Category: Mutual Funds
Mirae Asset Healthcare Fund Direct Growth Plan has a NAV of ₹52.378 as of 11 Sep 2026 and scheme AUM of ₹3,555 Cr. Its 1-year, 3-year and 5-year returns are 19.61%, 22.85% and 15.93%, and the scheme is tagged High Risk. Our view is that the fund has shown strong medium-term compounding, but investors need to be comfortable with sector concentration and benchmark swings.
The fund has also stayed ahead of the Nifty 50 over 1-year, 3-year and 5-year periods in the figures available here, which matters because healthcare can behave very differently from the broad market. The portfolio is focused on a small set of large healthcare names, so the returns are tied closely to sector leadership rather than broad diversification.
Quick facts
| Particular | Details |
|---|---|
| NAV | ₹52.378 as of 11 Sep 2026 |
| AUM | ₹3,555 Cr |
| Expense Ratio | 0.47% |
| Launch Date | 02 Jul 2018 |
| Min SIP | ₹99 |
| Risk Category | High Risk |
| Benchmark | Nifty 50 |
| Fund Category | Equity |
| Exit Load | 1% on or before 1Y(365D), Nil after 1Y(365D) |
| Fund Managers | Vrijesh Kasera, Tanmay Mehta |
The fund is managed by Vrijesh Kasera and Tanmay Mehta.
Source data date: as of 11 Sep 2026
Performance
| Period | Fund return | Benchmark return |
|---|---|---|
| 1M | 1.87% | -3.66% |
| 3M | 10.54% | -1.91% |
| 1Y | 19.61% | -7.62% |
| 3Y | 22.85% | 6.22% |
| 5Y | 15.93% | 5.84% |
The recent pattern is constructive. Over 1 month and 3 months, the fund moved upward while the benchmark stayed weak, so the scheme has been able to hold its ground even when the broader market index was softer. That is useful for a sector fund because investors usually want the strategy to do more than simply mirror the market.
The longer view is stronger still. The 1-year return is comfortably positive while the benchmark is negative, which means the fund has added value through a difficult market phase for the index. The 3-year and 5-year figures remain well above the benchmark too, so the medium-term compounding profile is intact rather than being just a short rally.
The time pattern also suggests some volatility along the way, with periods of drawdown and recovery instead of a smooth climb. That is consistent with a High Risk equity sector fund. For investors, the main takeaway is that returns have been driven by a fairly decisive rebound in the fund while the benchmark has lagged, especially over the last year.
In our view, the key question is not whether the fund has beaten the broad market in these periods, but whether an investor is comfortable with a healthcare-focused path to that outperformance. The answer will depend on the role this fund plays inside the rest of the portfolio.
Source data date: as of 11 Sep 2026
Should you BUY or HOLD Mirae Asset Healthcare?
A fund’s past returns alone don’t tell you whether you should buy it today or continue holding it.
The right decision depends on factors such as your current allocation, purchase price, risk profile, investment horizon and the role this fund plays in your overall portfolio.
Already holding Mirae Asset Healthcare? Thinking of investing now?
Peer comparison
| Fund | 1Y return | 3Y return | 5Y return |
|---|---|---|---|
| Mirae Asset Healthcare Fund Direct Growth Plan | 19.61% | 22.85% | 15.93% |
| ICICI Pru Strategic Metal and Energy Equity FoF Direct Growth Plan | 69.16% | 37.12% | Data not available |
| Motilal Oswal Active Momentum Fund Direct Growth Plan | 30.67% | Data not available | Data not available |
| Kotak Healthcare Fund Direct Growth Plan | 28.09% | Data not available | Data not available |
| HDFC Pharma and Healthcare Fund Direct Growth Plan | 27.47% | Data not available | Data not available |
| SBI Automotive Opportunities Fund Direct Growth Plan | 27.05% | Data not available | Data not available |
This assessment is prepared by Uniapps Investment Adviser Pvt. Ltd. under SEBI Registered Investment Adviser registration INA000017639. On the available 1-year figures, the fund trails the strongest peer returns in this set, but it remains competitive with the other healthcare and thematic strategies listed. The 3-year picture is more balanced: the fund’s 22.85% compares well with the only peer in this list that has a 3-year figure, while the 5-year figure is harder to benchmark because most peer entries do not have that history available. That means the short-term comparison is clearly different from the longer-term story.
Source data date: as of 11 Sep 2026
Want to know more? Log in to Univest for more mutual fund insights.
Portfolio: where your money goes
| Holding | Sector | Weight |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 10.90% |
| Divi’S Laboratories Ltd. | Healthcare | 9.91% |
| Torrent Pharmaceuticals Ltd. | Healthcare | 7.06% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 5.91% |
| Laurus Labs Ltd. | Healthcare | 5.24% |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 4.99% |
| DR. Reddy’S Laboratories Ltd. | Healthcare | 3.94% |
| Aurobindo Pharma Ltd. | Healthcare | 3.81% |
| Ipca Laboratories Ltd. | Healthcare | 3.43% |
| Fortis Healthcare Ltd. | Healthcare | 3.40% |
The top 10 holdings account for approximately 58.59% of the portfolio.
To see all holdings, visit the Mirae Asset Healthcare Fund Direct Growth Plan page
The largest holding, Sun Pharmaceutical Industries Ltd., carries a 10.90% weight, so it is large enough to matter meaningfully to day-to-day portfolio behaviour. The next few holdings are also sizeable, but the weights step down from 9.91% to 3.40% by the tenth row, which shows that influence is spread across several major positions rather than resting on one stock alone.
Even so, the displayed holdings are still fairly concentrated. The top 10 positions together make up 58.59% of the portfolio, and the full disclosed list contains 28 holdings, so the remaining positions likely form a longer tail. That combination may give the fund a clear healthcare tilt while still allowing multiple companies to influence returns if the sector is moving in different pockets.
For investors, this mix means the fund may respond strongly when leading healthcare names are in favour, but it could also feel uneven if only a few holdings are carrying the sector. The concentration level is not extreme for a sector fund, yet it is high enough that stock selection within healthcare is likely to matter.
Source data date: as of 11 Sep 2026
Who should invest
This fund fits investors who can handle High Risk equity exposure and are comfortable with a sector-led return pattern. The 1-year, 3-year and 5-year returns show that the scheme has been able to beat the benchmark over the periods shown, but the journey has not been smooth.
A longer horizon is more appropriate than a short trading-style view, because the fund’s portfolio is built around healthcare names and the recent return path shows normal sector volatility. The main trade-off is clear: investors may get stronger upside when healthcare is in favour, but they also need to accept that returns can move differently from the broad market.
The fund is more suitable as a satellite allocation than as the core of a diversified portfolio, especially for investors who already understand the role of sector concentration. It is best viewed by those who want focused healthcare exposure and can stay invested through uneven stretches.
Tax and exit load
| Holding period | Tax rate | Description |
|---|---|---|
| Units held less than 1 year | 20% | Short-term capital gains tax |
| Units held more than 1 year | 12.5% | Long-term capital gains tax |
Exit load: 1% if units are sold within 1 year; nil after 1 year.
Source data date: as of 11 Sep 2026
Frequently asked questions
What is the current NAV of Mirae Asset Healthcare Fund Direct Growth Plan?
The current NAV is ₹52.378 as of 11 Sep 2026.
What are the fund’s 1-year, 3-year and 5-year returns?
Its 1-year return is 19.61%, the 3-year return is 22.85% and the 5-year return is 15.93%.
How does the fund compare with the Nifty 50?
It has outpaced the Nifty 50 over 1 year, 3 years and 5 years in the figures shown here. The benchmark return is -7.62% over 1 year, 6.22% over 3 years and 5.84% over 5 years.
How does it compare with the listed peer funds on 1-year returns?
Its 1-year return of 19.61% is below several of the listed peer returns, including 69.16%, 30.67%, 28.09%, 27.47% and 27.05%. The 3-year comparison is narrower because only one peer in the list has a 3-year figure available.
What is the minimum SIP amount?
The minimum SIP amount is ₹99.
What are the fund manager, risk and exit-load details?
The fund is managed by Vrijesh Kasera and Tanmay Mehta, and it is tagged High Risk. The exit load is 1% if units are sold within 1 year and nil after 1 year.
Bottom line
Mirae Asset Healthcare Fund Direct Growth Plan has a stronger longer-term record than the benchmark shown here, and its recent return profile has also stayed positive. The peer comparison is mixed: the fund is behind some of the strongest 1-year figures in the group, but the 3-year and 5-year context remains meaningful where data is available. The portfolio is concentrated in healthcare names, with Sun Pharmaceutical Industries Ltd. as the largest holding. That makes the fund suitable for investors who want focused sector exposure and can accept High Risk movement.
Published on 15 September 2026 at 4:37 PM IST
Explore mutual funds with Univest
Review mutual fund data, compare performance and explore fund insights on Univest.
RIA disclosure
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully before investing. This review is prepared by Uniapps Investment Adviser Pvt. Ltd. (earlier known as Uniapps Global Research Pvt. Ltd.) under SEBI Registered Investment Adviser registration INA000017639 for general informational purposes and is not personalized investment advice.